利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

33 条记录 (耗时 0.026 秒)

    Spray drying process and compositions of fenofibrate
    1.
    发明授权
    Spray drying process and compositions of fenofibrate 有权
    喷雾干燥工艺和非诺贝特组合物

    公开(公告)号：US06696084B2

    公开(公告)日：2004-02-24

    申请号：US09838593

    申请日：2001-04-20

    申请人： Gary W. Pace ,  Awadesh K. Mishra ,  Robert A. Snow ,  Indu Parikh ,  Pol-Henri W. Guivarc'h

    发明人： Gary W. Pace ,  Awadesh K. Mishra ,  Robert A. Snow ,  Indu Parikh ,  Pol-Henri W. Guivarc'h

    IPC分类号： A61K914

    CPC分类号： A61K31/66 ,  A61K9/145 ,  A61K9/1623 ,  A61K31/216 ,  A61K31/22 ,  A61K31/365 ,  A61K31/40 ,  A61K31/405 ,  A61K31/44 ,  A61K31/505 ,  A61K45/06 ,  A61K31/215 ,  A61K2300/00

    摘要： The present invention relates to a novel spray drying process for the preparation of pharmaceutical compositions containing small particles of phospholipid-stabilized fenofibrate. This invention also relates to spray dried powdered compositions prepared according to this process, and to dosage forms of fenofibrate (capsules, tablets, powders, granules, and dispersions) prepared from these powdered compositions. The powdered compositions and dosage forms are useful in the treatment of dyslipidemia and dyslipoproteinemia and have the advantage that they provide reduced in vivo variability in the bioavailability of fenofibrate active species among fed and fasted patients when administered orally.

    摘要翻译： 本发明涉及一种用于制备含有磷脂稳定的非诺贝特的小颗粒的药物组合物的新型喷雾干燥方法。 本发明还涉及根据该方法制备的喷雾干燥的粉末组合物，以及由这些粉末状组合物制备的非诺贝特（胶囊，片剂，粉末，颗粒剂和分散体）的剂型。 粉末组合物和剂型可用于治疗血脂异常和血脂异常，并且具有这样的优点：当口服给药时，它们在进食和禁食患者中提供非诺贝特活性物质的生物利用度的体内变异性降低。

    Cyclosporiine particles
    3.
    发明授权
    Cyclosporiine particles 有权

    公开(公告)号：US06465016B2

    公开(公告)日：2002-10-15

    申请号：US09750218

    申请日：2000-12-29

    申请人： Indu Parikh ,  Robert A. Snow

    发明人： Indu Parikh ,  Robert A. Snow

    IPC分类号： A61K914

    CPC分类号： B82Y5/00 ,  A61K9/145

    摘要： Pharmaceutical compositions containing solid cyclic oligopeptide cyclosporine microparticles are prepared by applying energy input to solid cyclic oligopeptide cyclosporine in the presence of phospholipid and one or more non-ionic, anionic or cationic second surface modifiers. The microparticles consist essentially of a solid cyclic oligopeptide cyclosporine core coated with a combination of phospholipid and at least one second surface modifier. The combination of phospholipid and second surface modifier(s) provide volume-weighted mean particle size values of solid cyclic oligopeptide cyclosporine particles that are about 50% smaller than cyclic oligopeptide cyclosporine particles produced in the presence of the phospholipid and without the presence of the second surface modifier(s) using the same energy input.

    Process for preparing a rapidly dispersing solid drug dosage form
    5.
    发明授权
    Process for preparing a rapidly dispersing solid drug dosage form 有权
    制备快速分散固体药物剂型的方法

    公开(公告)号：US07939105B2

    公开(公告)日：2011-05-10

    申请号：US09443863

    申请日：1999-11-19

    申请人： Indu Parikh ,  Awadhesh K. Mishra ,  Robert Donga ,  Michael G. Vachon

    发明人： Indu Parikh ,  Awadhesh K. Mishra ,  Robert Donga ,  Michael G. Vachon

    IPC分类号： A61K9/14 ,  A61K9/16

    CPC分类号： A61K9/145 ,  A61K9/19 ,  A61K47/26

    摘要： Rapidly dispersing solid dry therapeutic dosage form comprised of a water insoluble compound existing as a nanometer or micrometer particulate solid which is surface stabilized by the presence of at least one phospholipid, the particulate solid being dispersed throughout a bulking matrix. When the dosage form is introduced into an aqueous environment the bulking matrix is substantially completely dissolves within less than 2 minutes thereby releasing the water insoluble particulate solid in an unaggregated and/or unagglomerated state. The matrix is composed of a water insoluble substance or therapeutically useful water insoluble or poorly water soluble compound, a phospholipid and optionally also at least one non-ionic, anionic, cationic or amphipathic surfactant, together with a matrix or bulking agent and if needed a release agent. The volume weighted mean particle size of the water insoluble particle is 5 micrometers or less.

    摘要翻译： 快速分散固体干燥治疗剂型，其由存在于由至少一种磷脂存在而表面稳定的纳米或微米颗粒固体的水不溶性化合物组成，颗粒状固体分散在整个填充基质中。 当将剂型引入含水环境中时，膨胀基质在少于2分钟内基本上完全溶解，由此以非聚集和/或未聚集状态释放水不溶性颗粒固体。 基质由水不溶性物质或治疗上有用的水不溶性或难溶于水的化合物，磷脂和任选地至少一种非离子阴离子阳离子或两性表面活性剂以及基质或填充剂组成，如果需要， 脱模剂。 水不溶性颗粒的体积加权平均粒径为5微米以下。

    Cyclosporin emulsions
    6.
    发明授权
    Cyclosporin emulsions 失效
    环孢菌素乳剂

    公开(公告)号：US5660858A

    公开(公告)日：1997-08-26

    申请号：US627187

    申请日：1996-04-03

    申请人： Indu Parikh ,  Awadhesh Mishra

    发明人： Indu Parikh ,  Awadhesh Mishra

    IPC分类号： A61K9/107 ,  A61K31/00 ,  A61K38/00 ,  A61K38/13 ,  A61P37/00 ,  A61P37/06 ,  A61K35/13

    CPC分类号： A61K9/1075 ,  A61K38/13 ,  Y10S514/938 ,  Y10S514/943

    摘要： This invention comprises pharmaceutical compositions consisting essentially of an oil-in-water emulsion containing a synthetic medium chain triglyceride in which is dissolved a therapeutically effective amount of a cyclosporin, phospholipid and optionally free fatty acid or a salt thereof, non-ionic surfactant, ionic surfactant, glycerol, salts, buffers, preservative, osmotic modifier and antioxidant.

    摘要翻译： 本发明包括主要由含有合成中链甘油三酯的水包油乳液组成的药物组合物，其中溶解有治疗有效量的环孢菌素，磷脂和任选的游离脂肪酸或其盐，非离子表面活性剂，离子 表面活性剂，甘油，盐，缓冲液，防腐剂，渗透调节剂和抗氧化剂。

    Mucin hypersecretion inhibitors and methods of use
    8.
    发明授权
    Mucin hypersecretion inhibitors and methods of use 有权
    粘蛋白分泌过多的抑制剂和使用方法

    公开(公告)号：US08492518B2

    公开(公告)日：2013-07-23

    申请号：US12430662

    申请日：2009-04-27

    申请人： Indu Parikh

    发明人： Indu Parikh

    IPC分类号： C07K7/06

    CPC分类号： C07K7/06 ,  A61K38/00 ,  C07K5/1008 ,  C07K5/101 ,  C07K5/1013 ,  C07K5/1016 ,  C07K5/1019 ,  C07K5/1021 ,  C07K5/1024 ,  C07K14/4703 ,  C07K14/4727

    摘要： Peptides are provided that comprise less than 24 amino acids. The peptides have an amino acid sequence selected from the group consisting of: (a) an amino acid sequence having from 4 to 6 contiguous amino acids of a reference sequence PEPTIDE 1; (b) an amino acid sequence substantially identical to the sequence defined in (a); and (c) a variant of the amino acid sequence defined in (a). Also provided is a non-myristoylated MANS peptide. Various methods of using the peptides are also provided.

    摘要翻译： 提供包含少于24个氨基酸的肽。 所述肽具有选自以下的氨基酸序列：（a）具有参考序列PEPTIDE 1的4至6个连续氨基酸的氨基酸序列; （b）与（a）中定义的序列基本相同的氨基酸序列; 和（c）（a）中定义的氨基酸序列的变体。 还提供了非肉豆蔻酰化的MANS肽。 还提供了使用多肽的各种方法。

    Methods for attenuating release of inflammatory mediators and peptides useful therein
    10.
    发明授权
    Methods for attenuating release of inflammatory mediators and peptides useful therein 有权
    用于减轻其中有用的炎性介质和肽的释放的方法

    公开(公告)号：US08999915B2

    公开(公告)日：2015-04-07

    申请号：US12359892

    申请日：2009-01-26

    申请人： Indu Parikh

    发明人： Indu Parikh

    IPC分类号： A61K38/08 ,  A61K38/17 ,  A61K38/10

    CPC分类号： A61K38/16 ,  A61K38/08 ,  A61K38/10 ,  A61K38/17 ,  A61K45/06

    摘要： The present invention includes methods of inhibiting or suppressing cellular secretory processes. More specifically the present invention relates to inhibiting or reducing the release of inflammatory mediators from inflammatory cells by inhibiting the mechanism associated with the release of inflammatory mediators from granules in inflammatory cells. In this regard, the present invention discloses an intracellular signaling mechanism that illustrates several novel intracellular targets for pharmacological intervention in disorders involving secretion of inflammatory mediators from vesicles in inflammatory cells. Peptide fragments and variants thereof of MANS peptide as disclosed in the present invention are useful in such methods.

    摘要翻译： 本发明包括抑制或抑制细胞分泌过程的方法。 更具体地，本发明涉及通过抑制与炎性细胞中的颗粒释放炎症介质相关的机制来抑制或减少炎性介质从炎性细胞释放。 在这方面，本发明公开了一种细胞内信号传导机制，其说明了在炎性细胞中从囊泡分泌炎症介质的病症中的药理学干预的几种新的细胞内靶标。 如本发明所公开的MANS肽的肽片段及其变体在这些方法中是有用的。